scholarly journals Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial

2002 ◽  
Vol 87 (8) ◽  
pp. 3609-3617 ◽  
Author(s):  
Pierre D. Delmas ◽  
Kristine E. Ensrud ◽  
Jonathan D. Adachi ◽  
Kristine D. Harper ◽  
Somnath Sarkar ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Vertebral Fracture ◽  
Fracture Risk ◽  
Postmenopausal Women ◽  
Risk Reduction ◽  
Randomized Clinical Trial ◽  
Vertebral Fracture Risk ◽  
Fracture Risk Reduction

scholarly journals Sustained Vertebral Fracture Risk Reduction After Withdrawal of Teriparatide in Postmenopausal Women With Osteoporosis

2004 ◽  
Vol 164 (18) ◽  
pp. 2024 ◽  
Author(s):  
Robert Lindsay ◽  
Wim H. Scheele ◽  
Robert Neer ◽  
Gerhardt Pohl ◽  
Silvano Adami ◽  
...  
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Postmenopausal Women ◽  
Risk Reduction ◽  
Vertebral Fracture Risk ◽  
Fracture Risk Reduction

scholarly journals Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis

2019 ◽  
Vol 105 (3) ◽  
pp. 938-943 ◽  
Author(s):  
Benjamin Z Leder ◽  
Bruce Mitlak ◽  
Ming-yi Hu ◽  
Gary Hattersley ◽  
Richard S Bockman
Keyword(s):  
Vertebral Fracture ◽  
Fracture Risk ◽  
Postmenopausal Women ◽  
Risk Reduction ◽  
Vertebral Fractures ◽  
Statistical Significance ◽  
Fracture Rate ◽  
Alendronate Treatment ◽  
Clinical Fractures ◽  
Fracture Risk Reduction

Abstract Context The ACTIVE study demonstrated the antifracture efficacy of abaloparatide in postmenopausal women with osteoporosis. ACTIVExtend demonstrated sustained fracture risk reduction with alendronate in abaloparatide-treated participants from ACTIVE. A direct comparison of the efficacy of abaloparatide and antiresorptive therapies has not been performed. Objective The objective of this analysis is to compare the antifracture efficacy of abaloparatide in ACTIVE with that of alendronate in ACTIVExtend. Design In this post hoc analysis, the rate of new vertebral fractures for women in ACTIVExtend (N = 1139) was calculated based on baseline and endpoint radiographs for placebo or abaloparatide in ACTIVE and alendronate in ACTIVExtend. Vertebral fracture rates between abaloparatide and alendronate were compared in a Poisson regression model. Fracture rates for nonvertebral and clinical fractures were compared based on a Poisson model during 18 months of abaloparatide or placebo treatment in ACTIVE and 18 months of alendronate treatment in ACTIVExtend. Results The vertebral fracture rate was lower during abaloparatide treatment in ACTIVE (0.47 fractures/100 patient-years) than alendronate treatment in ACTIVExtend (1.66 fractures/100 patient-years) (relative risk reduction 71%; P = .027). Although the comparisons did not meet statistical significance, after switching from placebo (ACTIVE) to alendronate (ACTIVExtend), the rate of new vertebral fractures decreased from 2.49 to 1.66 fractures per 100 patient-years, and after switching from abaloparatide to alendronate from 0.47 to 0.19 fractures per 100 patient-years. The rates of nonvertebral fractures and clinical fractures were not significantly different. Conclusion Initial treatment with abaloparatide may result in greater vertebral fracture reduction compared with alendronate in postmenopausal women with osteoporosis.

Sign in / Sign up

Export Citation Format

Share Document